Repere Therapeutics Presents Positive Data from MYTHIC Phase 1 Trial for Gynecologic Cancers

Repare Therapeutics Inc. recently disclosed positive outcomes from their MYTHIC Phase 1 trial in gynecologic expansion, focusing on the combination of lunresertib and camonsertib (“Lunre+Camo”). The trial aimed at evaluating the recommended Phase 2 dose (RP2D) in patients with endometrial cancer (EC) and platinum-resistant ovarian cancer (PROC) harboring lunre-sensitizing biomarkers. The Company’s press release highlighted these significant findings.

The results, showcased on December 12, 2024, suggested that Lunre+Camo therapy exhibited favorable tolerability and promising outcomes when compared to existing and upcoming treatments for various solid tumor types. The most common adverse event observed was anemia.

Key details from the MYTHIC trial’s recent data cut included a comprehensive analysis of patients with endometrial cancer. Among the noteworthy findings were a 25.9% confirmed overall response rate (ORR) and a significant clinical benefit noted in 48.1% of patients. Notably, durable clinical benefit was observed in nearly half of these patients at the 24-week landmark analysis.

The evaluation also extended to patients with platinum-resistant ovarian cancer. Out of the 24 evaluated patients, a 37.5% ORR and a 77.3% clinical benefit rate were reported, demonstrating meaningful responses even after 12 weeks of treatment. The 24-week progression-free survival rate was notably at 45%.

Repare Therapeutics has engaged with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency to gather insights for their registrational development plan involving Lunre+Camo in gynecologic tumors. The Company is gearing up to submit Phase 3 registrational trial protocols shortly, with plans to kickstart the initial Phase 3 trial in endometrial cancer in the latter half of 2025. Additionally, they intend to initiate a smaller contribution of components trial in up to 40 endometrial cancer patients in early 2025.

In conclusion, Repare Therapeutics emphasizes the promising potential of Lunre+Camo therapy as a prospective treatment option and standard of care for patients with endometrial and platinum-resistant ovarian cancers in the near future. Moreover, the Company remains focused on navigating the regulatory landscape and advancing their clinical development plans effectively.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Repare Therapeutics’s 8K filing here.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.